Solum Healthcare Partners with IQURE to Meet Global Cosmetics Demand

by SHIN JIA Posted : June 29, 2026, 18:28Updated : June 29, 2026, 18:28
Overview of Solum Headquarters
Overview of Solum Headquarters [Photo=Solum Healthcare]
Solum Healthcare is making a strategic investment in partnership with IQURE to respond to global buyer demand for cosmetics.

According to industry sources on June 29, Solum Healthcare will participate in a third-party capital increase worth 21 billion won through its subsidiary, Solum Cosmetic, by forming a consortium with external partners. This investment will be conducted solely by Solum Healthcare without financial support from its parent company. The collaboration with IQURE, which has manufacturing capabilities, aims to align with the increasing supply requests from global buyers following the integration of GDK Cosmetics.

Since being incorporated into Solum Healthcare, GDK Cosmetics has reported a 35% increase in sales and a 64% rise in operating profit within just one year. The expansion of Solum's global distribution network has facilitated greater connections with overseas buyers.

A representative from Solum stated, "This strategic investment in IQURE is a decision made in response to changing customer requests. While there has been a continuous demand, GDK Cosmetics alone could not address these areas effectively."

The collaboration is expected to combine GDK Cosmetics' years of experience in ODM operations for basic cosmetics with IQURE's advanced functional mask pack line and dermatological manufacturing capabilities, leading to the development of new product lines. Given that IQURE also operates in the pharmaceutical sector, its strengths in functional areas are likely to become more pronounced. The synergy with Solum's global distribution channels is also anticipated to be significant.

A Solum Healthcare official remarked, "GDK Cosmetics and IQURE complement each other in both portfolio and client relationships, making this collaboration not just about scale but about delivering greater value to customers." The transaction is expected to be finalized by August 2026, following the necessary approvals from relevant authorities.

Additionally, Shinshin Pharmaceutical, a representative player in the domestic pharmaceutical market, will participate as a strategic investor in this consortium.



* This article has been translated by AI.